Oxford, UK – Oxford Gene Technology (OGT), provider of innovative clinical

genetics and diagnostic solutions to advance molecular medicine, and Biotype Diagnostics GmbH

are pleased to announce the completion of a licence agreement granting Biotype access to OGT

patents for the detection of DNA sequence variations. The licence, which will remain valid for the

lifetime of the patents, provides Biotype with certain rights with respect to SNP genotyping.

Sue Sutton, VP Business Development at OGT, said: “OGT continues to develop its licensing

programme and is pleased to license our sequence variation patents to Biotype. These patents are

an important part of OGT’s broad patent portfolio and, together with Biotype’s microarray platform,

gives customers access to a new, comprehensive way of detecting commercially important woodrotting fungi.”

Wilhelm Zorgiebel, Executive Director at Biotype, commented: “We are pleased to enter into this

licensing arrangement with OGT, a company that is recognised as being at the forefront of

molecular technology. This agreement helps us to develop our own microarray technology platform

for various applications in medicine and analytics. Our first product, which is completely unique in

the market, is the Mycotype® BasidioQS Microarray Detection Kit, which allows the fast and

sensitive, simultaneous analysis of the 27 most important wood-rotting basidiomycetes in Europe.”

www.ogt.co.uk